The Latest Cardiac and Vascular News
DENVER and MARLBOROUGH, Mass., Nov. 2, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced final five-year outcomes data from the PREVAIL study of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device today during a late-breaking clinical trial session at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in Denver. The […]
MARLBOROUGH, Mass., Oct. 26, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.222 billion during the third quarter ended September 30, 2017. This represents growth of 5.6 percent on a reported basis and 5.7 percent on an operational basis (excludes the impact of changes in foreign currency exchange rates), all compared to the […]
MARLBOROUGH, Mass., Oct. 23, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced key data that will be presented at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in Denver, on October 29 – November 2. WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device data will be featured in a […]
Boston Scientific shared the 3-year MAJESTIC DES data online at CardioVascular and Interventional Radiology MAJESTIC 3-Year Data Published for Boston Scientific’s Eluvia DES, by Endovascular Today October 11, 2017—The 3-year results of the MAJESTIC first-in-human study of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) for treating femoropopliteal artery lesions were published […]
MARLBOROUGH, Mass., Oct. 2, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation (AF). The transaction consists of $175 million in cash up-front and a maximum […]
The Federal court upheld a previous coronary stent win over Dr. David Jang Appeals court upholds Boston Scientific win over stent pioneer Jang BY BRAD PERRIELLO, MassDevice A federal appeals court today upheld a Boston Scientific (NYSE:BSX) win over coronary stent pioneer Dr. David Jang. The case dates back to 1999, when Jang won […]
MARLBOROUGH, Mass., Sept. 25, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) has launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure Diagnostic to help physicians improve heart failure (HF) management. The new devices, which are approved by the U.S. Food […]
DALLAS and MARLBOROUGH, Mass., Sept. 19, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart Failure Patients (MultiSENSE) study evaluating the performance of the HeartLogic Heart Failure Diagnostic to predict impending heart failure (HF) decompensation. Data from the study were presented as a late-breaking clinical […]
PENANG, 11 April 2016 – Expanding its manufacturing footprint in the Asia Pacific region, Boston Scientific Corporation (NYSE: BSX) today marked the commencement of construction work on a regional manufacturing hub during a groundbreaking ceremony in Penang. Located at the Batu Kawan Industrial Park, the completion of the facility is planned […]
FREMONT, Calif. and ST. LOUIS, Sept. 11, 2017 /PRNewswire/ — VENITI®, Inc., a leader in the advancement of treatment for deep venous disease, today announced that Boston Scientific will distribute the VICI VENOUS STENT under a limited global distribution agreement. The terms of the agreement and specific regions and countries involved were not disclosed. Launched […]
